At GBT, we collaborate with academic centers to present and publish key results at medical conferences and in peer-reviewed publications. For additional information related to our data presentations and publications, please contact 1-833-GBT-4YOU (1-833-428-4968) or visit the GBT Online Form.

Voxelotor Data Publications

Real-World Data on Voxelotor to Treat Patients with Sickle Cell Disease
European Journal of Haematology, Muschick et al, April 2022

Safety and Efficacy of Voxelotor in Pediatric Patients with Sickle Cell Disease Aged 4 to 11 Years
Pediatric Blood & Cancer, Estepp et al, April 2022

Real-world Effectiveness of Voxelotor for Treating Sickle Cell Disease in the US: a Large Claims Data Analysis
Expert Review of Hematology, Shah et al, February 2022

Voxelotor in Adolescents and Adults with Sickle Cell Disease (HOPE): Long-term Follow-up Results of an International, Randomised, Double-blind, Placebo-controlled, Phase 3 Trial
The Lancet Haematology, Howard et al, April 2021

The Impact of Voxelotor Treatment on Leg Ulcers in Patients With Sickle Cell Disease 
American Journal of Hematology, Minniti et al, January 2021

A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease 
New England Journal of Medicine, Vichinsky et al, June 2019

Pharmacokinetics and Pharmacodynamics of Voxelotor (GBT440) in Healthy Adults and Patients With Sickle Cell Disease
British Journal of Clinical Pharmacology, Hutchaleelaha et al, February 2019

A Phase 1/2 Ascending Dose Study and Open-Label Extension Study of Voxelotor in Patients with Sickle Cell Disease
Blood, Howard et al, January 2019

Impact of Voxelotor (GBT440) on Unconjugated Bilirubin and Jaundice in Sickle Cell Disease: A Patient Case Report
Hematology Reports, Telfer et al, May 2018

Case Series of Patients with Severe Sickle Cell Disease Treated with Voxelotor (GBT440) by Compassionate Access
American Journal of Hematology, Blyden et al, May 2018